CN104688765A - Composition stomach medicine made from alginates - Google Patents
Composition stomach medicine made from alginates Download PDFInfo
- Publication number
- CN104688765A CN104688765A CN201310636697.7A CN201310636697A CN104688765A CN 104688765 A CN104688765 A CN 104688765A CN 201310636697 A CN201310636697 A CN 201310636697A CN 104688765 A CN104688765 A CN 104688765A
- Authority
- CN
- China
- Prior art keywords
- alginate
- aluminium
- alginic acid
- stomach medicine
- stomach
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a composition stomach medicine made from alginates. The composition stomach medicine is composed of aluminum alginate and potassium alginate at a random weight ratio. Generally, the composition stomach medicine comprises 5 to 95wt% of aluminum alginate, and the balance potassium alginate. Aluminum alginate in the composition stomach medicine can be replaced by a mixture of alginic acid and aluminium hydroxide dried gel. Adult average body weight is assumed to be 60kg, so that aximum daily dosage of aluminum alginate ranges from 0.6 to 4.5g, and maximum daily dosage of potassium alginate ranges from 0.6 to 3.72g. After consumption of the composition stomach medicine, a layer of gel film is formed on human stomach walls, and is capable of protecting gastric mucosa from stimulation caused by gastric acid. Aluminum alginate can not be absorbed in digestive tract, so that long-term consumption is possible.
Description
[technical field] the present invention relates to a kind of prescription stomach medicine combined by alginate.
[background technology] alginate jelly is as full-bodied colloid, someone reports very early for its sodium salt, potassium salt, it has good therapeutical effect to digestive tract ulcer, various types of gastritis, and aluminium alginate or share by alginic acid and gel aluminum hydroxide, also there is good therapeutical effect to ulcer and reflow gastritis.Aluminium alginate is the trivalent salt of alginic acid, and experiment proves, it has good Healing to rat experiment gastric ulcer, has good therapeutical effect to reflow gastritis.
The salt of alginic acid is called as alginate.Alginic acid is colourless, the polysaccharide containing carboxyl of that have the L-guluronic acid inserted once in a while, that Isosorbide-5-Nitrae-glycosidic bond connects D-MANNOSE aldehydic acid unit, and belongs to polysaccharide aldehyde acids.Alginic acid can account for the high 40wt% to Brown algae dry.The magnesium salt of the alkali metal salt of alginic acid, the ammonium salt of alginic acid and alginic acid is water miscible.Particularly sodium alginate, is also referred to as algin, has very large importance as thickening agent, emulsifying agent or emulsion stabilisers and as the basis of gel in food, medicine and cosmetics industry.On the contrary, as alginic acid, calcium alginate and alginic acid zinc are water-insoluble.By joining in sodium alginate gel by water-insoluble calcium alginate, the viscosity of the latter can be increased.
Know that calcium alginate is for the preparation of alginic acid fiber and the purposes of wound dressing be made up of alginic acid fiber.Alginic acid fiber is prepared by extracting alginic acid by sodium carbonate liquor from Sargassum.The sodium alginate soln obtained is purified and is pressed into containing CaCl
2in the precipitated liquid of weak acid solution.
EP0586260A1 describes the alginate agent of fiber paste form, and this alginate agent has the alginate content of 2 ~ 11wt%, and by preparing with the aqueous solution process water-insoluble of solubilising salt or the alginic acid fiber of water-swellable.
United States Patent (USP) 5,470,576 disclose a kind of preparation method containing the wound dressing of alginate, wherein, by soaking into this fabric by softness, absorptive textile impregnation to sodium alginate aqueous solution with alginate, then adding calcium chloride wherein and precipitating to make calcium alginate.Design these wound dressings and make, when itself and Wound contact, there is anastalsis.
EP0783605B1 is described containing alginic acid fiber and the wound dressing prepared with solidification by alginate and the cellulosic cospinning of water-soluble carboxymethyl; Described alginate has cross-linked form, and fiber has the G content of at least 35wt% by the alginate of its cospinning.
EP1435247A1 relates to and a kind ofly comprises alginic acid fiber fabric and the multilayered wound dressing of layer not with Wound contact and containing superabsorbers.
WO02/36866A1 discloses has water absorption, the polysaccharide fiber of preferred alginate or alginate and the combination as another polysaccharide material of absorption enhancement carboxymethyl cellulose, and this polysaccharide fiber contains silver compound as antibacterial activity agent.WO02/36866A1 also describes the wound dressing be made up of these polysaccharide fibers.
WO03/022317A1 describes a kind of antibacterial wound dressing based on the such as gel formation fiber of carboxymethyl cellulose or alginic acid fiber, and silver ion is evenly combined with described wound dressing by the part of available cation reversibility binding site.
In addition, also useful alginate makes the relevant report of food and capsule, if notification number is " a kind of manufacture method of alginate jelly " that CN101422212B patent specification is introduced, described alginate jelly batching comprises A and B two parts, it is the alginate of 54 ~ 65%, the water-retaining agent of 5 ~ 10% that component A comprises percentage by weight, and B component comprises the gellant of 20 ~ 28% and the retarder of 5 ~ 12%.
Before the present invention completes, there is not yet the relevant report of the prescription stomach medicine combined by alginate.
[summary of the invention] the object of the present invention is to provide a kind of prescription stomach medicine combined by alginate.Particularly a kind of prescription stomach medicine combined by aluminium alginate.
Above-mentioned purpose of the present invention is achieved through the following technical solutions.
The prescription stomach medicine combined by alginate, is characterized in that said prescription stomach medicine is made up of the aluminium alginate component of any weight percent proportioning and potassium alginate component.
The use in the formulation of described aluminium alginate, can use with aluminium alginate form, also can replace using with the mixture of alginic acid and aluminium hydroxide desiccant gel.
Generally, the weight percent proportioning of described aluminium alginate component is 5 ~ 95%, and surplus is potassium alginate component.To be grown up, average weight 60kg calculates, and the maximum consumption per day of aluminium alginate is 0.6-4.5g, and the maximum consumption per day of potassium alginate is 0.6-3.72g.This use amount does not comprise the network water in alginic acid, alginate and the water of crystallization in aluminium hydroxide desiccant gel.
Described potassium alginate and aluminium alginate, the molecular weight of its acid group alginic acid is between 60,000-25 ten thousand.
Experimentation of the present invention proves:
One, aluminium alginate is to the Healing of rat Experimental Gastric Ucler.
1, the preparation of acetic acid gastric ulcer model is tested
Adopt the rat of 160-260 gram of body weight, male and female regardless of, adopt the feedwater of normality feed balance feed, 24 h fast before formal analogue formation, utilize full folder method to make acetic acid and stomach wall contacts 60 seconds, blot acetic acid afterwards and clean coat of the stomach with normal saline, suturing them.
2, adopt the aluminium alginate of about 20 Wan Daoertun, be made into the concentration suspensions of 0.2%, aluminium alginate applies with the form of mixtures of alginic acid and aluminium hydroxide desiccant gel.
Select matched group 12 rats and experimental group 12 rats, every morning 10 gavages once, matched group take normal saline as blank experiment.Medicinal liquid and void volume are 2ml.
3, the method for inspection of ulcer healing:
At the position of stomach outer wall through acetic acid treatment, just form ulcer, namely occur concave at gastric wall opposite position, the volume of concave is large, illustrates that ulcer is serious.Respectively to experimental group rat and the blank ulcer concave position saline injection organizing rat, the volume of the normal saline injected by each group, the order of severity of ulcer can be found out, namely cumulative volume is large, illustrate that its ulcer level is large, the healing of less its ulcer of explanation is better, can calculate the healing rate of ulcer according to following formula.
The meansigma methods of the ulcer volume in formula, refers to the test Mus quantity of each test group ulcer concave cumulative volume divided by this group:
Result of calculation is as follows:
| Group | Dosage | Animal number of cases | Ulcer volume mean | Healing rate |
| Blank group | 12 | 24.5μl | ||
| Aluminium alginate group | 40mg/kg | 12 | 10.2μl | 58.3％ |
4, the discussion of mechanism:
Alginate jelly, as full-bodied colloid, after perfusion, can form one deck colloidal film; be attached on the coat of the stomach of experimental mouse, make its gastric mucosa from the stimulation of gastric acid, although alginate jelly can not the secretion of gastric acid inhibitory; but gastric mucosa epidermis cell can be protected, and then play and impel incarnant effect.Aluminium alginate belongs to partial neutral salt.
Aluminium alginate can form one deck mucous membrane protection gastric mucosal cell, and this aluminium alginate is the trivalent salt of sea acid, compared with a salt as Na
+, K
+, NH
4 +salt etc. and two portions of salt are as Ca
++, Mg
++etc. there being better gelling, and aluminium alginate is not easily absorbed in digestive tract, can take the normal phase.
The detection of aluminium alginate then adopts alginate routine inspection method, and adopts CO
2volume quantitative or with aluminum quantitative method.With Dextran T polysaccharide for reference substance, 0.1mol NaCl is the molecular weight determination of eluent, can measure the molecular weight of the acid group alginic acid of above-mentioned aluminium alginate and potassium alginate, and its method is that alginic acid is prepared into monovalent salt, measure its molecular weight, then calculate the molecular weight of its alginic acid.
The computational methods of ulcer healing rate: administration is after 10 days, by sacrifice of animal, cut open the belly, and by cardia and pylorus ligation, formalin (i.e. formaldehyde) 5-10ml 5% injects gastric, again stomach is taken out, to insert in 5% formalin solution 10 minutes, then along greater gastric curvature, stomach is cut, use normal saline flushing stomach, after rinsing well, gastric mucosa is upwards spread on white porcelain tile, ulcer portion sets level as far as possible, blot with the normal saline of absorbent paper by ulcer portion, then with the 100ml injector filling normal saline, lentamente saline is instilled in ulcer concave surface, until be just full of, record injects the salt water yield, be the volume of ulcer, by the healing rate of aforesaid formulae discovery ulcer, obtain the exterior and the interior institute column data.
Form of being used as medicine due to aluminium alginate can be share with the desiccant gel of alginic acid and aluminium hydroxide, therefore, enter in stomach and can not form mucosa immediately, can solve so clinically, namely a certain amount of potassium alginate is added, form a kind of prescription stomach medicine preventing and treating gastropathy, be made up of component aluminium alginate and potassium alginate.
Rational formula (C
6h
7o
6k) n, its acid group alginic acid mean molecule quantity is comparatively suitable from 6 ten thousand to 25 ten thousand, the univalent metal salt of this alginic acid, enter in stomach and can form mucosa immediately, be attached on coat of the stomach, about a slaine of alginic acid is to the therapeutical effect of gastric ulcer, existing people's report in the past, and after potassium alginate forms mucosa, alginic acid and aluminium hydroxide react the effectiveness that then can play them.On the other hand, potassium alginate is a kind of strong base-weak acid salt, can give in coat of the stomach and form a kind of alkali condition, be conducive to the neutralization of alginic acid and gel aluminum hydroxide.But due to 60,000-25 ten thousand mean molecule quantities, the excipient of the even larger potassium alginate to 350,000 mean molecule quantities inherently medicine, therefore, potassium alginate can not occur with the identity of main composition, and occurs with the identity of excipient.
The use amount of aluminium alginate is 40mg/kg, enter to receive after alginic acid and aluminium hydroxide can being prepared into extra large acid filling aluminum, also can use together with aluminium hydroxide with alginic acid, the molal weight ratio of the two is 1: 1, by acute toxinology experiment allow using dosage and minimum effective day use amount dosage range be 10mg/kg to 75mg/kg.In the average weight 60kg that is grown up, consumption per day 0.6-4.5g.
And the safe handling scope of potassium alginate and ADI value are 62mg/kg.In the average weight 60kg that is grown up, maximum consumption per day is 3.72g.
The using dosage of above aluminium alginate and potassium alginate does not all comprise AI (OH)
3the water of crystallization of desiccant gel and alginic acid, the network moisture content of potassium alginate.
The present invention compared with prior art has the following advantages and good effect:
1, alginate jelly is as full-bodied colloid, can form one deck colloidal film after taking medicine, and is attached on the coat of the stomach of people, makes its gastric mucosa from the stimulation of gastric acid.Although alginate jelly can not the secretion of gastric acid inhibitory, gastric mucosa epidermis cell can be protected, and then play and impel incarnant effect.
2, aluminium alginate belongs to partial neutral salt, can form one deck mucous membrane protection gastric mucosal cell, and this aluminium alginate is the trivalent salt of sea acid, compared with a salt as Na
+, K
+, NH
4 +salt etc. and two portions of salt are as Ca
++, Mg
++etc. there being better gelling, and aluminium alginate is not easily absorbed in digestive tract, can take the normal phase.
3, the aluminium alginate component that adopts of this prescription stomach medicine and potassium alginate component, resource is wide, and toxic and side effects is little.Wherein the primary raw material of aluminium alginate is Thallus Laminariae (Thallus Eckloniae), after being processed into alginic acid, changes into the aluminum salt of trivalent further, or is share by alginic acid and aluminium hydroxide desiccant gel, also can change into aluminium alginate by seaweed industry.
[detailed description of the invention]
Embodiment 1
Pulverize and sieve, mix homogeneously, load hard capsule 1,000,000, every 0.5g, active component 40-60%, adult every day 2-4 time, each 2-4 grain.
Primary raw material be Thallus Laminariae (Thallus Eckloniae), after being processed into alginic acid by seaweed industry, change into the aluminum salt of trivalent further, or share by alginic acid and aluminium hydroxide desiccant gel, also can change into aluminium alginate
Its consumption per day scope is 10mg/kg-75mg/kg, 10mg/kg-62mg/kg, and this use amount does not comprise the network water in alginic acid, alginate and the water of crystallization in Bismuth hydrate. desiccant gel.
Claims (4)
1. the prescription stomach medicine combined by alginate, is characterized in that said prescription stomach medicine is made up of the aluminium alginate component of any weight percent proportioning and potassium alginate component.
2. prescription stomach medicine according to claim 1, it is characterized in that the weight percent proportioning of said aluminium alginate component is 5 ~ 95%, surplus is potassium alginate component.
3. prescription stomach medicine according to claim 1 and 2, is characterized in that said aluminium alginate is the mixture of alginic acid and aluminium hydroxide desiccant gel.
4. prescription stomach medicine according to claim 1 and 2, is characterized in that said potassium alginate and aluminium alginate, and the mean molecule quantity of its acid group alginic acid is between 60,000-25 ten thousand.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310636697.7A CN104688765A (en) | 2013-12-04 | 2013-12-04 | Composition stomach medicine made from alginates |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310636697.7A CN104688765A (en) | 2013-12-04 | 2013-12-04 | Composition stomach medicine made from alginates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104688765A true CN104688765A (en) | 2015-06-10 |
Family
ID=53336591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310636697.7A Pending CN104688765A (en) | 2013-12-04 | 2013-12-04 | Composition stomach medicine made from alginates |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104688765A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105754012A (en) * | 2016-03-21 | 2016-07-13 | 青岛海之林生物科技开发有限公司 | Preparation process of aluminum magnesium alginate |
| CN105754013A (en) * | 2016-03-21 | 2016-07-13 | 青岛海之林生物科技开发有限公司 | Preparation process of magnesium potassium alginate |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN85104754A (en) * | 1984-04-19 | 1986-12-10 | 罗勒国际(海外)有限公司 | The manufacture method of antacid composition |
| CN101926818A (en) * | 2008-12-25 | 2010-12-29 | 天津康鸿医药科技发展有限公司 | Medicine composition containing tea polyphenol and alginic acid and application thereof |
| CN101933894A (en) * | 2009-07-03 | 2011-01-05 | 张清 | Protecting colloid for gastroenteric mucosa |
-
2013
- 2013-12-04 CN CN201310636697.7A patent/CN104688765A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN85104754A (en) * | 1984-04-19 | 1986-12-10 | 罗勒国际(海外)有限公司 | The manufacture method of antacid composition |
| CN101926818A (en) * | 2008-12-25 | 2010-12-29 | 天津康鸿医药科技发展有限公司 | Medicine composition containing tea polyphenol and alginic acid and application thereof |
| CN101933894A (en) * | 2009-07-03 | 2011-01-05 | 张清 | Protecting colloid for gastroenteric mucosa |
Non-Patent Citations (1)
| Title |
|---|
| 齐刚等: "海藻酸铝抗溃疡作用的研究", 《中草药》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105754012A (en) * | 2016-03-21 | 2016-07-13 | 青岛海之林生物科技开发有限公司 | Preparation process of aluminum magnesium alginate |
| CN105754013A (en) * | 2016-03-21 | 2016-07-13 | 青岛海之林生物科技开发有限公司 | Preparation process of magnesium potassium alginate |
| CN105754012B (en) * | 2016-03-21 | 2018-03-13 | 青岛海之林生物科技开发有限公司 | A kind of preparation technology of alginic acid magnalium |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101584824B1 (en) | Osmolyte-containing Preparation for the Treatment of Dry Mucous Membranes | |
| CN105013001B (en) | A kind of gynecological medical biological hydrogel functional dressings and preparation method thereof | |
| CN108159024A (en) | A kind of sustained release pad pasting for treating canker sore and preparation method thereof | |
| CN105381159B (en) | It is a kind of for treat burn compound aloe barbadensis Miller polysaccharide external-use gel | |
| CN104688765A (en) | Composition stomach medicine made from alginates | |
| ES2959546T3 (en) | Liquid composition for use in the treatment of the mucosa of the oro-pharyngo-laryngo-esophageal tract | |
| CN103006700B (en) | PH buffer activity glass and its production and use | |
| CN104069535B (en) | A kind of Preparation method and use of biological activity composite membrane bleeding-stopping dressing | |
| JPH08502030A (en) | Biocidal composition containing mustard seed plant extract | |
| EP3370700B1 (en) | Oral gel composition comprising chitosan, pectin, l-carnitine and n-acetylcysteine | |
| CN101023961B (en) | Medicine composition containing sodium hyaluronate and zinc salt | |
| CN103007043A (en) | Combined traditional Chinese medicine for treating respiratory tract infections of livestock and fowls | |
| CN100496507C (en) | Hydroxyethyl starch injection liquid and preparation method thereof | |
| US20160000131A1 (en) | Methods and Formulations for Enhancing Hydration | |
| DE102017113203A1 (en) | Medical use of potassium hydroxide | |
| WO2022064415A1 (en) | Compositions comprising a vegetable chondroitin or an analogue thereof and the use thereof in the treatment of disorders of the mucous membrane of the oral, pharyngo-laryngeal and/or gastro-oesophageal tract | |
| CN100496508C (en) | Policresulen gelling agent, method for preparation the same and the pharmaceutical use thereof | |
| CN100415773C (en) | Carboxymethyl chitosan potassium zinc bismuth and preparation process and application thereof | |
| CN101785761A (en) | Compound hemostasis medicine and preparation method thereof | |
| JPS6072817A (en) | Improvement of iron (11) salt, zinc salt, magnesium salt salt and mixed salt of them as substitute of iron, zinc and magnesium | |
| WO2010108494A1 (en) | Dayspepsia treatment with alginate | |
| RU2356557C2 (en) | Homeopathic medicine for treatment and prevention of endometritis in animals | |
| WO2023026231A1 (en) | Composition for the prevention and/or treatment of gastric and esophageal diseases | |
| EP2117502B1 (en) | Composition for combating epistaxis | |
| CN105963338B (en) | Prevent and treat the herbal composite of cervical erosion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| DD01 | Delivery of document by public notice |
Addressee: Rich sunshine (Dalian) Industrial Co., Ltd. Document name: Notification of Publication of the Application for Invention |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150610 |